BPC-157 + TB-500 Blend Side Effects and Safety
Reported BPC-157 + TB-500 Blend side effects, contraindications, and safety signals.
Side Effects
Preclinical animal studies have demonstrated a favorable safety profile for BPC-157, with no acute toxicity observed across multiple organ systems, including liver, spleen, lung, kidney, brain, thymus, prostate, and ovaries at doses ranging from 6 μg/kg to 20 mg/kg over 6-week periods. However, human clinical safety data remain extremely limited. Anecdotal reports from users have included: Injection site pain, redness, or swelling The FDA has noted that BPC-157 may pose an immunogenicity risk (triggering an immune response). Additionally, because BPC-157 products are unregulated, contamination with other substances represents a significant concern, and some studies suggest that between 12% and 58% of ergo-nutritional supplements may be contaminated with other substances.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
IV BPC-157 infusion up to 20 mg was well-tolerated with no adverse effects in 2 healthy adults.
Contraindications
- active malignancy
- pregnancy
References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015.
- Thymosin β4 Promotes Dermal Healing.
- Gene ResultTMSB4X thymosin beta 4 X-linked [ (human)] - NCBI